Primary Job Title Senior Vice President and Chief Technology Officer Primary Organization 
Anthera Pharmaceuticals
Gender Female
LinkedIn View on LinkedIn
Dr. Odink is the Chief Development Officer of LQT Therapeutics. Over the course of 30 years, she has been involved in pharmaceutical development across the spectrum of large and small molecules. She started her career at Roche working in manufacturing process development and characterization of several of Roche's early-stage programs. After
Roche, she began her career in start-up, venture-backed biotech, first at Peninsula advancing a sterile filled antibiotic from pre-clinical to NDA which was acquired by Johnson and Johnson. At Anthera Pharmaceuticals, as the Chief of Technical Operations, she advanced two products into phase 3, one a small molecule enzyme inhibitor targeting inflammation and the other a large molecule peptide for lupus. At Eiger Biopharmaceuticals, she was SVP, Technical Operations advancing four of Eiger’s rare disease programs into the clinic, one of which was recently approved. At SiteOne Therapeutics, she served as Chief Development Officer and was instrumental in advancing a novel non-opioid pain therapeutics into the clinic. She obtained her Ph.D. in chemistry from the University of California, Davis, and B.S. in chemistry from California State University, Stanislaus.
